Comprehensive Hearing and Vision Loss Panel

In general, there is a genetic basis for up to 50% of prelingual hearing loss and up to 60% of congenital blindness among infants. Indications for genetic testing for deafness and/or vision loss may include

  • Clinical status: To confirm a clinical diagnosis in an affected patient, in an individual with unknown status (who has not received screening or evaluation), or in unaffected relatives of an affected patient (who have had normal screenings and/or evaluations). The purpose of the test may be diagnostic, carrier testing, familial follow-up on a known family variant, or prenatal testing for known variant(s)
  • Treatment: To clarify the cause of hearing and/or vision loss, provide information on the likelihood of related health issues, and guide treatment
  • Family risk: To establish risk to other family members and future generations. Genetic testing can help family members who are susceptible to certain drugs avoid drug-induced hearing loss. For example, aminoglycoside drugs can cause hearing loss in individuals with mutations in the MT-RNR1 gene. Furthermore, testing can confirm syndromic conditions, enabling early detection and surveillance for defects in other organs

The Comprehensive Hearing and Vision Loss Panel detects pathogenic variants in 308 genes. It encompasses two smaller panels-the Comprehensive Vision Loss Panel (250 genes) and the Comprehensive Hearing Loss Panel (92 genes). Testing can be customized if you would like to order a hearing-specific or vision-specific gene panel. Targeted familial testing is also available.

Our customizable targeted next-generation sequencing (NGS) panel uses Agilent SureSelect™ target enrichment and Illumina HiSeq sequencing. NGS technology is ideal for diagnostic testing of these disorders due to the extreme locus heterogeneity and phenotype overlap of the genes involved. The sensitivity of this panel is estimated at 99% for single-base substitutions.

If indicated, Sanger sequencing may be performed in both directions using BigDye Terminator chemistry with the ABI 3730 DNA analyzer with target specific amplicons. It may also be used to supplement specific guaranteed target regions that fail NGS sequencing or as a confirmatory method for NGS positive results. NGS technology may not detect all small insertions or deletions. Additionally, it is not diagnostic for large duplications or deletions, repeat expansions, and structural genomic variation. Therefore, multiplex ligation-dependent probe amplification (MLPA) and oligonucleotide array comparative genomic hybridization (aCGH) are available for this test for deletion/duplication analysis. MLPA copy number analysis is available for the DFNB1 (GJB2/GJB6) locus, OTOA, and STRC. This MLPA testing is approximately 99% accurate. The customized oligonucleotide microarray is a highly-targeted, exon-focused array capable of detecting microdeletions and microduplications at a much higher resolution than traditional aCGH methods. The sensitivity of the aCGH assay is estimated to be greater than 99% for medically-relevant microdeletions and microduplications in the exonic regions of 304 genes. Copy number variation of MT-RNR1, P2RX2, STRC, and RAB28 will not be reported using aCGH.

Specimen Requirements


Please provide one of the following specimen types:

  • Two confluent T-25 flasks of cultured cells from amniotic fluid or chorionic villi
  • >4 mg of direct chorionic villi tissue
  • 15 mL of direct amniotic fluid

5-10 mL of blood in an EDTA tube (lavender top) is required from each biological parent. Parental blood samples may be used for maternal cell contamination studies or confirmation studies.

Whole blood

Newborn or child

  • One 2 mL EDTA tube (lavender top) or one 2 mL ACD-A or ACD-B tube (yellow top) from the patient
  • One 5-10 mL EDTA tube (lavender top) or one 5-10 mL ACD-A or ACD-B tube (yellow top) is also recommended from each biological parent


  • Two 5-10 mL EDTA tubes (lavender top) or two 5-10 mL ACD-A or ACD-B tubes (yellow top) from the patient
  • One 5-10 mL EDTA tube (lavender top) or one 5-10 mL ACD-A or ACD-B tube (yellow top) is also recommended from each biological parent

Extracted DNA

  • A minimum of 10 μL DNA (50-250 ng/μL) is required for testing. 20 μL DNA (50-350 ng/μL) is recommended


  • Saliva specimens are accepted upon request. Please contact our laboratory to obtain saliva kits
  • Saliva samples should be collected in Oragene DNA (OG-500) kits by DNA Genotek

Ordering Information


  • Tubes of blood, cultured cells, direct chorionic villus sampling, and direct amniotic fluid should be stored and shipped at room temperature or refrigerated
  • Do not freeze specimens
  • Please ship specimens same day or overnight to: 62 Southfield Ave, Stamford, CT 06902

Turnaround Time

  • Prenatal: 7-10 business days from receipt of specimen
  • Pediatric or adult: 3-4 weeks from receipt of specimen


Genetic Testing for Hearing and Vision Loss Test Requisition
Genetic Testing for Hearing and Vision Loss Clinical Information Sheet
Genetic Testing for Hearing and Vision Loss Brochure